UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 OR 15(d) ofOF ~~the Securities Exchange Act of 1934~~THE

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported): June 6, 2013 (February 11, 2013)~~1934

Date of Report (Date of earliest event reported):

November 18, 2013

Assured Pharmacy, Inc.
(Exact name of registrant as specified in its charter)

Nevada	~~333~~001-~~181361~~35735	98-0233878
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5600 Tennyson Parkway, Suite 390, Plano, Texas	75034
(Address of principal executive offices)	(Zip Code)

5600 Tennyson Parkway, Suite 390, Plano, Texas 75024

(Address of principal executive offices)

~~Registrant’s telephone number, including area code:~~ (972) 473-4033

~~2595~~Registrant's ~~Dallas~~telephone ~~Parkway~~number, ~~Suite~~including ~~206,~~area ~~Frisco, Texas 75034 (Former name or former address, if changed since last report)~~code

___________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 35.~~02 Unregistered~~07 ~~Sales~~- Submission of ~~Equity~~Matters ~~Securities~~to a Vote of Security Holders.

WeAssured ~~are filing this Current Report on Form 8-K to report that our previously announced private placement expired on May 30~~Pharmacy, ~~2013~~Inc. As ~~previously reported, in January 2013, we initiated a private placement~~ (the “~~Private Placement~~Company”) ofsubmitted ~~equity~~the ~~securities~~following inactions ~~Units,~~to ~~each~~be oftaken ~~which~~by ~~consisted~~consent of ~~(a)~~its ~~38,462~~shareholders ~~shares~~in lieu of ~~our common stock, $0.001 par value per share, valued at $0.65 per share; and (b)~~ a ~~three-year~~meeting ~~warrant~~in toits ~~purchase~~definitive upproxy ~~to 38~~statement,~~462~~ ~~shares~~as offiled ~~common stock~~ with ~~an initial exercise price of $0.90 per share (~~the ~~“Warrants”), subject to certain anti-dilution adjustments~~U.S. ~~The~~Securities ~~Units~~and ~~included~~Exchange ~~registration~~Commission ~~rights~~on ~~requiring~~October ~~us to cause the shares of common stock issuable upon exercise of the Warrants to be registered under the Securities Act of 1933~~29, as2013 ~~amended~~ (the “~~Securities~~Proxy ~~Act~~Statement”), within 45 days of the final closing date. If the shares of common stock issuable upon exercise of the Warrants are not covered by an effective registration statement after such time, they may be exercised on a cashless basis.:

We1. ~~previously~~Amend ~~reported~~and ~~that~~restate 20the ~~Units~~Articles ~~were~~of ~~sold~~Incorporation ~~pursuant~~of tothe aCompany ~~Subscription~~to ~~Agreement~~increase ~~dated~~the ~~February~~authorized 5,number ~~2013~~of ~~(as~~shares ~~disclosed in our Current Report on Form 8-K filed February 13, 2013). A total~~ of ~~14.4~~Common ~~additional~~Stock ~~Units~~available ~~were~~for ~~sold~~issuance onfrom ~~February 11th~~35, ~~April 9th~~000,000 ~~16th~~to ~~and 19th~~100, ~~and May 2nd and 7th~~000,000.

~~During~~2. ~~the~~Create ~~offering~~and ~~period,~~designate ~~we entered into Subscription Agreements with~~ a ~~total~~class of ~~eight~~Preferred ~~accredited~~Stock ~~investors~~called (the “~~Investors”),~~Series ~~pursuant~~D toPreferred ~~which we sold an aggregate of 34.4 units (the “Units~~Stock,”) atconsisting ~~a purchase price~~ of ~~$25~~15,000 ~~per~~shares ~~Unit~~of ~~(the “Unit Price”); accordingly~~stock, wepar ~~received~~value ~~gross proceeds of~~ $~~860,000~~0. As001 aper ~~result of the Private Placement~~share, ~~we issued a total of 1,323,093 shares of common stock~~ and ~~warrants~~designate to ~~purchase~~such upclass ~~to an aggregate~~ of ~~1,323,093 shares of common~~ stock~~. The~~ ~~Units~~those ~~were~~rights ~~not~~as ~~sold~~described ~~through~~in anthat ~~underwriter,~~certain ~~and~~Certificate accordingly there were no underwriting discounts or underwriting commissions involved. We did employ a placement agent for the Private Placement, to whom we paid and issued total placement agent commissions of ~~$32,800~~Designation ~~and~~attached ~~five~~as ~~year~~Exhibit ~~warrants~~B to ~~purchase~~the upCompany’s toProxy ~~an aggregate of 100,924 shares of Common Stock~~Statement.

~~The~~Voting ~~Units~~closed ~~were~~on ~~offered~~November ~~and~~18, ~~sold~~2013, ~~without~~at ~~general~~which ~~solicitation~~time ~~and~~both ~~for~~proposals ~~investment~~were ~~purposes~~approved ~~only,~~by an affirmative vote of a majority of the outstanding shares of the Company’s common and preferred stock entitled to ~~accredited~~vote ~~investors~~thereon. ~~(as~~As indicated in the Proxy Statement, the Company determined byOctober ~~signed~~8, ~~subscription~~2013 ~~documents)~~to inbe ~~reliance~~the onrecord ~~Section 4(2)~~date offor the ~~Securities~~determination ~~Act~~of shareholders entitled to notice of, ~~1933~~and (to vote upon, the ~~“Securities~~proposals. ~~Act”)~~With ~~and/or~~respect ~~Rule~~to ~~506~~each ofaction ~~Regulation~~submitted Dto ~~promulgated~~shareholder ~~thereunder~~vote, the shareholders voted as set forth below.

~~The~~Action ~~terms~~1: ofAs ~~the Private Placement triggered certain anti-dilution protections afforded~~ to ~~holders~~the ofincrease ~~our~~in ~~various~~the ~~classes~~number of ~~preferred~~shares ~~stock and convertible debentures. However, we reached an agreement with 100%~~ of ~~the~~Common ~~holders~~Stock ofavailable ~~our~~for ~~Series~~issuance Afrom ~~Preferred Stock~~35, ~~Series B Preferred Stock~~000,000 ~~Series C Preferred Stock, and all convertible debentures~~ to ~~(i) consent to the Private Placement~~100, ~~(ii) waive the “full ratchet” anti-dilution provisions of their securities in connection with the Private Placement~~000, ~~and (iii) accept~~000, ~~as a partial ratchet anti-dilution adjustment, a decrease in~~ the ~~current~~voting ~~conversion~~results ~~price~~were ofas such preferred stock and convertible debentures and current exercise price of related warrants to $0.90 per share. These agreements allowed us to complete the Private Placement without making certain anti-dilution adjustments.follows:

- 2 -

Number of Votes For:		Number of Votes Against:
9,629,829		496,897

Action 2:

As to the creation and designation of a class of Preferred Stock called the “Series D Preferred Stock,” the voting results were as follows:

Number of Votes For:		Number of Votes Against:
9,629,829		496,897

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~June~~November 620, 2013

ASSURED PHARMACY, INC., a Nevada corporation

By:	/s/ Robert DelVecchio
Name:	Robert DelVecchio
Title:	Chief Executive Officer

- 32 -

Filing Compare · ASSURED PHARMACY, INC.